{"transactions":[{"id":312735,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-26T23:00:11.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":668,"price":486.35,"value":324881.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025."}],"balance_after":18432,"source":{"system":"sec-edgar","filing":"0000875320-26-000106","document":"wk-form4_1772146808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000106/wk-form4_1772146808.xml","form_type":"4"}},{"id":312734,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-26T23:00:11.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":1627,"price":485.11,"value":789273.97,"ownership":{"direct":true},"balance_after":19100,"source":{"system":"sec-edgar","filing":"0000875320-26-000106","document":"wk-form4_1772146808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000106/wk-form4_1772146808.xml","form_type":"4"}},{"id":313153,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:06:25.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":817,"price":473.68,"value":386996.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025."}],"balance_after":20727,"source":{"system":"sec-edgar","filing":"0000875320-26-000082","document":"wk-form4_1771535181.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000082/wk-form4_1771535181.xml","form_type":"4"}},{"id":313152,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:06:25.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":2031,"price":489.46,"value":994093.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025."}],"balance_after":21544,"source":{"system":"sec-edgar","filing":"0000875320-26-000082","document":"wk-form4_1771535181.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000082/wk-form4_1771535181.xml","form_type":"4"}},{"id":313151,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:06:25.000Z","date":"2026-02-17","kind":"tax_withholding","planned":true,"acquired":false,"shares":1530,"price":483.75,"value":740137.5,"ownership":{"direct":true},"balance_after":23575,"source":{"system":"sec-edgar","filing":"0000875320-26-000082","document":"wk-form4_1771535181.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000082/wk-form4_1771535181.xml","form_type":"4"}},{"id":313150,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:06:25.000Z","date":"2026-02-17","kind":"grant","planned":true,"acquired":true,"shares":4962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on February 20, 2027."}],"balance_after":25105,"source":{"system":"sec-edgar","filing":"0000875320-26-000082","document":"wk-form4_1771535181.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000082/wk-form4_1771535181.xml","form_type":"4"}},{"id":313481,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-18T21:19:54.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1903,"price":487.76,"value":928207.28,"ownership":{"direct":true},"balance_after":20143,"source":{"system":"sec-edgar","filing":"0000875320-26-000060","document":"wk-form4_1771449589.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000060/wk-form4_1771449589.xml","form_type":"4"}},{"id":313869,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-12T21:50:06.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":1751,"price":460.43,"value":806212.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025."}],"balance_after":22046,"source":{"system":"sec-edgar","filing":"0000875320-26-000038","document":"wk-form4_1770933003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000038/wk-form4_1770933003.xml","form_type":"4"}},{"id":313868,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-12T21:50:06.000Z","date":"2026-02-10","kind":"tax_withholding","planned":true,"acquired":false,"shares":872,"price":468.41,"value":408453.52,"ownership":{"direct":true},"balance_after":23797,"source":{"system":"sec-edgar","filing":"0000875320-26-000038","document":"wk-form4_1770933003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000038/wk-form4_1770933003.xml","form_type":"4"}},{"id":314838,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-01-26T21:17:50.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":3883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026."}],"balance_after":24669,"source":{"system":"sec-edgar","filing":"0000875320-26-000012","document":"wk-form4_1769462267.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000012/wk-form4_1769462267.xml","form_type":"4"}},{"id":314837,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-01-26T21:17:50.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":3934,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026."}],"balance_after":20786,"source":{"system":"sec-edgar","filing":"0000875320-26-000012","document":"wk-form4_1769462267.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000012/wk-form4_1769462267.xml","form_type":"4"}},{"id":316933,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-11-19T21:06:15.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":434.58,"value":1086450.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025."}],"balance_after":16852,"source":{"system":"sec-edgar","filing":"0000875320-25-000236","document":"wk-form4_1763586372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000236/wk-form4_1763586372.xml","form_type":"4"}},{"id":1011176,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:19:31.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-01","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0001193125-25-259047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259047/ownership.xml","form_type":"4"}},{"id":1011175,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:19:31.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.98,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":45150},"source":{"system":"sec-edgar","filing":"0001193125-25-259047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259047/ownership.xml","form_type":"4"}},{"id":1011174,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:19:31.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":14.7,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001193125-25-259047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259047/ownership.xml","form_type":"4"}},{"id":1011173,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:19:31.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":4.44,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-25-259047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259047/ownership.xml","form_type":"4"}},{"id":325024,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-28T21:36:16.000Z","date":"2025-02-27","kind":"sale","planned":true,"acquired":false,"shares":2650,"price":475.34,"value":1259651.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024."}],"balance_after":19352,"source":{"system":"sec-edgar","filing":"0000875320-25-000127","document":"wk-form4_1740778570.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000127/wk-form4_1740778570.xml","form_type":"4"}},{"id":325023,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-28T21:36:16.000Z","date":"2025-02-26","kind":"tax_withholding","planned":true,"acquired":false,"shares":2482,"price":479.61,"value":1190392.02,"ownership":{"direct":true},"balance_after":22002,"source":{"system":"sec-edgar","filing":"0000875320-25-000127","document":"wk-form4_1740778570.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000127/wk-form4_1740778570.xml","form_type":"4"}},{"id":325180,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-26T21:09:43.000Z","date":"2025-02-25","kind":"sale","planned":true,"acquired":false,"shares":1767,"price":480.95,"value":849838.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024."}],"balance_after":24484,"source":{"system":"sec-edgar","filing":"0000875320-25-000107","document":"wk-form4_1740604171.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000107/wk-form4_1740604171.xml","form_type":"4"}},{"id":325179,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-26T21:09:43.000Z","date":"2025-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":1656,"price":483.28,"value":800311.68,"ownership":{"direct":true},"balance_after":26251,"source":{"system":"sec-edgar","filing":"0000875320-25-000107","document":"wk-form4_1740604171.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000107/wk-form4_1740604171.xml","form_type":"4"}},{"id":325787,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-19T21:26:19.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1529,"price":463.46,"value":708630.34,"ownership":{"direct":true},"balance_after":27907,"source":{"system":"sec-edgar","filing":"0000875320-25-000083","document":"wk-form4_1740000364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000083/wk-form4_1740000364.xml","form_type":"4"}},{"id":326071,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-14T21:08:32.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":6211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/24/2026."}],"balance_after":29436,"source":{"system":"sec-edgar","filing":"0000875320-25-000061","document":"wk-form4_1739567303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000061/wk-form4_1739567303.xml","form_type":"4"}},{"id":326174,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-12T21:29:52.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":1747,"price":459.83,"value":803323.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr.  Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024."}],"balance_after":23225,"source":{"system":"sec-edgar","filing":"0000875320-25-000037","document":"wk-form4_1739395783.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000037/wk-form4_1739395783.xml","form_type":"4"}},{"id":326173,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-12T21:29:52.000Z","date":"2025-02-10","kind":"tax_withholding","planned":true,"acquired":false,"shares":876,"price":467.98,"value":409950.48,"ownership":{"direct":true},"balance_after":24972,"source":{"system":"sec-edgar","filing":"0000875320-25-000037","document":"wk-form4_1739395783.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000037/wk-form4_1739395783.xml","form_type":"4"}},{"id":326557,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-06T21:21:56.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":4744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025."}],"balance_after":25848,"source":{"system":"sec-edgar","filing":"0000875320-25-000011","document":"wk-form4_1738876909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000011/wk-form4_1738876909.xml","form_type":"4"}},{"id":326556,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2025-02-06T21:21:56.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":5132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025."}],"balance_after":21104,"source":{"system":"sec-edgar","filing":"0000875320-25-000011","document":"wk-form4_1738876909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000011/wk-form4_1738876909.xml","form_type":"4"}},{"id":1281330,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T16:01:03.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":56400,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0000950170-25-014437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000095017025014437/ownership.xml","form_type":"4"}},{"id":332799,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-06-13T20:09:13.000Z","date":"2024-06-12","kind":"sale","planned":true,"acquired":false,"shares":7288,"price":478,"value":3483664.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 02/22/2024."}],"balance_after":15972,"source":{"system":"sec-edgar","filing":"0000875320-24-000174","document":"wk-form4_1718309345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000174/wk-form4_1718309345.xml","form_type":"4"}},{"id":332798,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-06-13T20:09:13.000Z","date":"2024-06-11","kind":"tax_withholding","planned":true,"acquired":false,"shares":6824,"price":481.96,"value":3288895.04,"ownership":{"direct":true},"balance_after":23260,"source":{"system":"sec-edgar","filing":"0000875320-24-000174","document":"wk-form4_1718309345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000174/wk-form4_1718309345.xml","form_type":"4"}},{"id":333726,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-05-16T20:12:02.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":14112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 05/19/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 05/14/2024 and the shares will vest on 06/10/2024."}],"balance_after":30084,"source":{"system":"sec-edgar","filing":"0000875320-24-000144","document":"wk-form4_1715890307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000144/wk-form4_1715890307.xml","form_type":"4"}},{"id":339125,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-27T21:44:07.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":883,"price":425.7,"value":375893.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023."}],"balance_after":15972,"source":{"system":"sec-edgar","filing":"0000875320-24-000101","document":"wk-form4_1709070192.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000101/wk-form4_1709070192.xml","form_type":"4"}},{"id":339124,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-27T21:44:07.000Z","date":"2024-02-23","kind":"tax_withholding","planned":true,"acquired":false,"shares":1654,"price":431.79,"value":714180.66,"ownership":{"direct":true},"balance_after":16855,"source":{"system":"sec-edgar","filing":"0000875320-24-000101","document":"wk-form4_1709070192.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000101/wk-form4_1709070192.xml","form_type":"4"}},{"id":339401,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-23T21:16:13.000Z","date":"2024-02-21","kind":"sale","planned":true,"acquired":false,"shares":1201,"price":421.77,"value":506545.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023."}],"balance_after":18509,"source":{"system":"sec-edgar","filing":"0000875320-24-000089","document":"wk-form4_1708722946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000089/wk-form4_1708722946.xml","form_type":"4"}},{"id":339698,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-21T21:23:49.000Z","date":"2024-02-20","kind":"sale","planned":true,"acquired":false,"shares":801,"price":420.79,"value":337052.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023."}],"balance_after":19710,"source":{"system":"sec-edgar","filing":"0000875320-24-000070","document":"wk-form4_1708550607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000070/wk-form4_1708550607.xml","form_type":"4"}},{"id":339697,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-21T21:23:49.000Z","date":"2024-02-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":1125,"price":420.58,"value":473152.5,"ownership":{"direct":true},"balance_after":20511,"source":{"system":"sec-edgar","filing":"0000875320-24-000070","document":"wk-form4_1708550607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000070/wk-form4_1708550607.xml","form_type":"4"}},{"id":339696,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-21T21:23:49.000Z","date":"2024-02-16","kind":"tax_withholding","planned":true,"acquired":false,"shares":1501,"price":424.01,"value":636439.01,"ownership":{"direct":true},"balance_after":21636,"source":{"system":"sec-edgar","filing":"0000875320-24-000070","document":"wk-form4_1708550607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000070/wk-form4_1708550607.xml","form_type":"4"}},{"id":340500,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-13T21:54:16.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":913,"price":420.24,"value":383679.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 8/22/2023."}],"balance_after":23137,"source":{"system":"sec-edgar","filing":"0000875320-24-000045","document":"wk-form4_1707861239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000045/wk-form4_1707861239.xml","form_type":"4"}},{"id":340499,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-13T21:54:16.000Z","date":"2024-02-09","kind":"tax_withholding","planned":true,"acquired":false,"shares":832,"price":422.74,"value":351719.68,"ownership":{"direct":true},"balance_after":24050,"source":{"system":"sec-edgar","filing":"0000875320-24-000045","document":"wk-form4_1707861239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000045/wk-form4_1707861239.xml","form_type":"4"}},{"id":341082,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-08T21:24:55.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":4743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that vests in installments beginning on 02/17/2025."}],"balance_after":24882,"source":{"system":"sec-edgar","filing":"0000875320-24-000020","document":"wk-form4_1707427484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000020/wk-form4_1707427484.xml","form_type":"4"}},{"id":341081,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-08T21:24:55.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":3934,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on  02/06/2024 and the shares will vest in installments beginning on 02/10/2024."}],"balance_after":20139,"source":{"system":"sec-edgar","filing":"0000875320-24-000020","document":"wk-form4_1707427484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000020/wk-form4_1707427484.xml","form_type":"4"}},{"id":341080,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2024-02-08T21:24:55.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":2326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation\ncommittee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024."}],"balance_after":16205,"source":{"system":"sec-edgar","filing":"0000875320-24-000020","document":"wk-form4_1707427484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000020/wk-form4_1707427484.xml","form_type":"4"}},{"id":1658038,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T20:15:11.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":45150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 45,150 shares of the Issuer's Common Stock, which will vest in full on February 1, 2025, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":45150,"derivative":{"exercise_price":9.98,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":45150},"source":{"system":"sec-edgar","filing":"0000950170-24-011474","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000095017024011474/ownership.xml","form_type":"4"}},{"id":1865991,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T17:03:24.000Z","date":"2023-06-01","kind":"exercise","planned":false,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 6,250 shares of the Issuer's Common Stock, which vested in full on May 16, 2023."}],"balance_after":0,"derivative":{"exercise_price":2.61,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0000950170-23-026422","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000095017023026422/ownership.xml","form_type":"4"}},{"id":1865990,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T17:03:24.000Z","date":"2023-06-01","kind":"sale","planned":false,"acquired":false,"shares":6250,"price":17.91,"value":111937.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on January 30, 2023 in multiple trades at prices ranging from $17.53 to $18.18. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-026422","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000095017023026422/ownership.xml","form_type":"4"}},{"id":1865989,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T17:03:24.000Z","date":"2023-06-01","kind":"exercise","planned":false,"acquired":true,"shares":6250,"price":2.61,"value":16312.5,"ownership":{"direct":true},"balance_after":6250,"source":{"system":"sec-edgar","filing":"0000950170-23-026422","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000095017023026422/ownership.xml","form_type":"4"}},{"id":1971177,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T17:18:08.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, which vests in equal installments on February 17, 2023, February 17, 2024 and February 17, 2025, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":4.44,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-23-007032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924323007032/doc4.xml","form_type":"4"}},{"id":1971176,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-03T17:18:08.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":10000,"price":13.6,"value":136000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $13.49 to $14.83. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-007032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924323007032/doc4.xml","form_type":"4"}},{"id":1971175,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-03T17:18:08.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":10000,"price":4.44,"value":44400.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-23-007032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924323007032/doc4.xml","form_type":"4"}},{"id":2019309,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-13T17:33:20.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":27400,"derivative":{"exercise_price":14.7,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0000899243-23-004796","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924323004796/doc4.xml","form_type":"4"}},{"id":2252633,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T16:15:28.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 6,250 shares of the Issuer's Common Stock, which will vest in full on May 16, 2023, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":6250,"derivative":{"exercise_price":2.61,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0000899243-22-019926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924322019926/doc4.xml","form_type":"4"}}]}